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ABSTRACT:  The  developing  world  is  disproportionately  burdened  with  high  rates  of  maternal
mortality.  Despite widespread reduction in maternal deaths due to improved antepartum, intrapartum,
and postpartum care in developed nations, mortality rates are persistently high in many countries
unable  to  provide  advanced  medical  care.    Postpartum  haemorrhage  accounts  for  a  substantial
proportion of maternal deaths in developing countries.  This review addresses the clinical management
strategies aimed at the prevention and treatment of postpartum haemorrhage that are effective in low-
resource settings.  The review was conducted by searching the English-language medical literature
using  MEDlINE  (1950  -  Feb  2009)  and  the  online  search  engine  Google  Scholar.    Four  relevant
strategies were identified in the literature: active management of the third stage of labour (AMSTl),
the use of uterotonic agents including misoprostol, accurate measurement of blood loss, and internal
and external compression techniques.  Despite known intervention options, additional research on
effective  management  strategies  and  their  implementation  is  needed  to  address  postpartum
haemorrhage in countries of the developing world.     
INTRODUCTION 
Healthy mothers are the focus of United Nations’ Fifth
Millennium  Development  Goal,  with  the  aim  of
lowering  maternal  mortality  ratios  by  75%  between
1990  and  2015  (1).    Despite  reduction  in  maternal
deaths  amongst  transitional  and  developed  countries,
maternal mortality remains a significant cause of death
for women of reproductive age in the developing world.
This fact is exemplified by statistics collected by the
WHO, which show that 99% of the world’s half-million
annual maternal deaths occur in developing countries
(2).  Lifetime risk of maternal death is as high as one in
six for women living in the world’s poorest nations, a
figure in sharp contrast to a risk of one in 30,000 for
women in Northern Europe (3).  Substantial progress is
required before the targets of Goal No. 5 are met, and
increasingly  this  progress  must  be  seen  within  the
nations  disproportionately  burdened  by  maternal
deaths.   
Maternal mortality can be conceptualised as a direct
result of obstetrical complication leading to death, or
indirectly from a previously existing disease for which
pregnancy exacerbates the pathology or contributes to
increased severity of illness.  Direct causes account for
the great majority of maternal deaths in the developing
world (3).  A systematic review conducted by the WHO
found that postpartum haemorrhage is the leading cause
of maternal mortality in Africa and Asia, accounting for
up to half of the total number of deaths in these regions
(4).  Overall, postpartum haemorrhage accounts for an
estimated  25%  of  maternal  mortality  worldwide  (2).
Hypertensive  disorders  such  as  eclampsia  were
identified  as  the  leading  causes  of  death  in  Latin
America and the Caribbean; other prevalent causes of
maternal  mortality  include  sepsis,  obstructed  labour,
and complications with abortion (2).  
This review addresses the question of which clinical
management  strategies  are  effective  in  treating
postpartum  haemorrhage  in  the  developing  world.
Relevance of management options to the low-resource
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settings  characteristic  of  developing  countries  is
especially considered.  While equally important health
infrastructure and policy interventions are necessary to
decrease  maternal  mortality  in  developing  countries
(2,3), these are not the focus of this review.  
METHODS 
A search of the available English-language medical
literature was undertaken using MEDLINE (1950-Feb.
2009)  and  an  online  search  engine,  Google  Scholar.
Terms  used  in  searches  included  combinations  of
“maternal  mortality”,   “postpartum  haemorrhage/
hemorrhage”,  “labor/labour  complications”,  and
“developing  countries.”    Abstracts  from  potentially
relevant publications were read for content and included
in the review if they addressed the clinical management
of postpartum haemorrhage in a developing country or
low-resource setting.   
ClINICAl MANAGEMENT OF POSTPARTUM
HAEMORRHAGE
Postpartum haemorrhage is defined as blood loss of
more than 500 mL within 24 hours of vaginal delivery.
Blood loss may be associated with retained or adherent
placenta, trauma to tissue and vessels during delivery,
uterine atony, or coagulopathies such as fibrinolysis and
afibrinogenaemia  (5).    The  known  risk  factors  for
postpartum haemorrhage include prolonged third stage
of  labour,  multiple  delivery,  fetal  macrosomia,
episiotomy,  and  previous  history  of  postpartum
haemorrhage (6,7).  Postpartum haemorrhage may have
a predilection toward certain ethnicities; however, this
is not a consistent finding.  In a low-resource setting,
advanced maternal age and low parity have been shown
to  associate  with  a  higher  risk  of  haemorrhage  (8).
Importantly,  postpartum  haemorrhage  may  occur  in
obstetrical  patients  with  an  absence  of  known  risk
factors (3,8).  
The clinical management of postpartum haemorrhage
has not been systematically assessed with respect to the
reduction  of  maternal  mortality  in  the  context  of
developing countries.  Indeed, maternal mortality has
been  used  as  a  primary  outcome  in  only  a  few
randomised  controlled  trials,  largely  because  of  the
unethical nature of withholding care that is obviously
life-saving, but also as a result of the necessary sample
size requirements to show an effect on mortality (9).
Fortunately, clinical management strategies to prevent
or reduce blood loss due to postpartum haemorrhage
have been more broadly considered in the literature (9-
27).  This review identified four management strategies
relevant  to  the  topic  of  postpartum  haemorrhage  in
developing  countries:  the  active  management  of  the
third stage of labour, the use of uterotonic agents, early
and  accurate  blood  loss  estimation,  and  compression
techniques to reduce blood loss.       
Active Management of the Third Stage of Labour
Active  management  of  the  third  stage  of  labour
(AMTSL)  is  comprised  of  therapies  and
pharmacological treatment directed at reducing the risk
of postpartum haemorrhage.  This management strategy
is in contrast to “expectant” management of the third
stage of labour, whereby therapeutic intervention to aid
in  the  expulsion  of  the  placenta  is  not  performed.
Modalities  of  treatment  in  AMTSL  include  the
administration  of  a  uterotonic  agent,  umbilical  cord
traction, fundal massage, and may or may not include
early  cord  clamping  (10).    A  large  randomised
controlled trial found evidence that AMSTL reduced the
odds of postpartum haemorrhage by half compared to
non-active delivery of the placenta (OR=0.50, 95%CI
0.34-0.73)  (11).    These  findings  were  reflected  in  a
retrospective  cohort  study  with  historical  controls
conducted  in  a  developing  country,  which  found  a
significant  reduction  in  incidence  of  postpartum
haemorrhage  after  implementation  of  AMSTL
management (10).  The evidence is in favour of AMTSL
as a relatively inexpensive and effective management
modality  for  controlling  postpartum  haemorrhage  in
developing  countries,  providing  the  technique  is
performed appropriately.  Evidence from a Cochrane
Review (12) on active versus expectant management is
consistent  with  this  recommendation:  significantly
reduced  odds  of  postpartum  haemorrhage  were
observed with the use of AMSTL in the meta-analysis
of Khan and colleagues (11), which focussed on the
developing world.  Side effects of nausea, vomiting, and
raised  blood  pressure  were  more  strongly  associated
with AMSTL than expectant management, though these
were  considered  less  adverse  than  the  higher  risk  of
postpartum  haemorrhage  found  with  expectant
management (10-12).    
Misoprostol as a Uterotonic Agent
Uterotonic  agents  are  administered  during  active
management  of  the  third  stage  of  labour  to  promote
uterine  contractions  and  the  expulsion  of  placental
tissue  (10,12,13,15,19).    Regarding  the  appropriate
choice of uterotonic agent, oxytocin is favoured for the
medical  management  of  postpartum  haemorrhage,
based  on  a  large,  multicentre  randomised  controlled
trial conducted by the WHO (13).  This study showed
that oxytocin is associated with significantly less risk of
haemorrhage (3% versus 4% incidence in the oxytocin
and  misoprostol  groups  respectively,  p<0.001)  and
fewer side effects than misoprostol (13).  This result is
consistent with a Cochrane systematic review, whichPost-partum Hemorrhages  63 Vol. 12  No. 2
assessed 37 trials from both developed and developing
nations and concluded that oxytocin is more effective
than misoprostol against postpartum haemorrhage and
associated  sequelae  (14).    Smaller  randomised
controlled  trials  conducted  specifically  in  developing
countries  found  significant  evidence  of  reduced
postpartum  haemorrhage  risk  with  misoprostol
compared  to  placebo  (15,16),  and  some  reported  no
difference  when  compared  to  oxytocin  (17,18).   The
above studies concluded that misoprostol is effective as
a  uterotonic  agent  to  prevent  and  treat  postpartum
haemorrhage.  
The  choice  of  uterotonic  agent  for  treatment  of
postpartum haemorrhage in developing countries must
be  considered  in  the  context  of  both  expense  and
thermostability.    Costly  or  heat-labile  preparations
requiring refrigeration may be difficult or impossible to
use in low-resource settings (17,18).  Misoprostol is a
relatively  inexpensive,  thermostable  uterotonic  agent
which can be administered orally, rectally, or vaginally
(16-19).  This makes it a likely candidate for effective
medical  prevention  and  management  of  postpartum
haemorrhage  in  the  developing  world  despite  the
therapeutic advantage provided by oxytocin, which is
more  expensive,  heat-labile,  and  requires  IV  or  IM
administration (19).  Given that oxytocin may provide
an advantage over misoprostol and is associated with
fewer  side-effects,  its  use  in  areas  with  refrigeration
capability  and  adequate  financing  is  favoured  over
misoprostol  in  settings  where  AMSTL  is  the  norm
(13,14,19).    However,  in  low-resource  settings,
misoprostol  should  be  considered  as  an  alternative
primary treatment for postpartum haemorrhage.
Early and Accurate Estimation of Blood Loss
Not surprisingly, the severity of clinical outcomes for
postpartum haemorrhage correlates with the amount of
blood lost, and for this reason, the early and accurate
estimation  of  blood  loss  is  vitally  important  to  the
clinical management of the postpartum bleeding patient
(20).  Low-resource settings may not have access to
standardised  blood  collection  tools,  however,  novel
approaches  developed  to  estimate  blood  loss  may
provide effective alternatives.  For example, Patel and
colleagues describe the effectiveness of an inexpensive
blood collection drape used in India to estimate blood
loss against visual assessment alone.  Estimates based
on  the  drape  correlated  well  with  photospectrometry
and were more accurate than visual assessment alone,
which tended to underestimate the amount of blood lost
(21).  This suggests the tool provides an appropriate
measurement that can be easily and inexpensively made
in low-resource settings.  Geller and colleagues indicate
that this system is now used in eight countries (22).  A
similar collection system used in Tanzania provides a
consistent measure of blood loss with the use of kanga,
a type of blanket with standard dimensions that is used
regionally in East Africa and holds approximately 250
mL of blood when soaked (23).  The effectiveness of
blood  loss  estimation  using  these  techniques  has  not
been established empirically with respect to postpartum
haemorrhage  outcomes.    However,  standardised,
accurate measurement tools would theoretically allow
birth  attendants  to  more  easily  recognise  postpartum
haemorrhage  in  a  systematic  way,  resulting  in
opportunities  for  intervention  and  appropriate
management.   Although  these  approaches  have  been
described in only a handful of studies, they demonstrate
the  importance  of  solutions  that  are  regionally
acceptable and relevant—such as calibrated measures in
Tanzania based on the amount of blood absorbed by a
kanga.        
External and Internal Compression 
Blood  loss  resulting  from  postpartum  haemorrhage
may  be  managed  with  the  use  of  compression
techniques  suited  or  adapted  to  use  in  low-resource
settings.    Abdominal  compression  of  the  aorta  may
decrease blood loss in severe postpartum haemorrhage
if performed correctly (24).  This manoeuvre is easy to
perform  and  requires  little  equipment,  thus  it  would
present fewer barriers to implementation in developing
countries than many other therapies.  However, there is
a  dearth  of  evidence  showing  that  abdominal
compression of the aorta significantly reduces negative
outcomes  associated  with  postpartum  haemorrhage
specifically.  Intrauterine tamponade with the use of a
condom and rubber catheter has been suggested as an
affordable  alternative  to  blood  loss  management  in
severe postpartum haemorrhage refractory to uterotonic
therapy.  The evidence for this technique is based on
several  series  of  case  reports,  the  largest  of  which
involved  23  obstetric  patients  and  was  conducted  in
Bangladesh (25).  
DISCUSSION 
The proper management of postpartum haemorrhage
is  an  essential  component  of  obstetric  care  and  a
necessary step in the goal to reduce worldwide maternal
mortality.  The literature is replete with evidence for
best  practices  and  appropriate  therapies,  particularly
with  respect  to  uterotonic  agents  and  active
management of the third stage of labour.  However, the
interventions predominantly identified in the research
and clinical settings of developed countries may not be
feasible in the low-resource settings characteristic of the
developing world (9, 22, 26).  Strategies that prevent
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accessible, affordable, and have uncomplicated storage
requirements in order to be effective in countries with
limited healthcare financing and infrastructure.  A ready
example of this phenomenon is the suggested use of
misoprostol  as  a  uterotonic  agent  in  the  absence  of
resources  that  make  the  provision  of  the  superior
therapy  (oxytocin)  possible.   An  urgent  need  for  the
uptake of technologies proven to work in developing
countries has been identified.  Furthermore, continued
research  into  the  effectiveness  of  postpartum
haemorrhage  interventions  in  the  context  of  low-
resource  settings  is  required  to  better  understand  the
clinical  management  of  this  obstetrical  complication.
These needs extend beyond postpartum haemorrhage to
include the other direct and indirect causes of maternal
mortality  in  the  developing  world.    Contextually
appropriate strategies to manage hypertensive disorders
(e.g.  eclampsia),  sepsis,  obstructed  labour,  and
complications related to abortion have been identified
but still require implementation to be effective against
maternal mortality (9, 26).        
This  review  identified  four  clinical  management
strategies for postpartum haemorrhage, however a fifth
clinical  consideration  needs  also  to  be  addressed,
although  it  is  not  specific  to  reduced  postpartum
haemorrhage  alone:  the  presence  of  skilled  birth
attendants during delivery.  These healthcare workers
and  midwives  possess  (at  least  theoretically)  a
minimum skill set necessary to take a detailed history,
provide antenatal care, perform a vaginal exam, time
and assess uterine contractions, and otherwise manage
normal labour and recognise the need to refer in the
presence  of  complications  (27).    The  availability  of
skilled  birth  attendants  during  delivery  may  be  an
important step toward maternal mortality reduction, as
suggested  by  ecological  data  from  the  WHO  (28).
However,  caution  must  be  exercised  with
recommendations regarding skilled attendance at birth.
Intrapartum  care  is  largely  dependent  on  setting,
transportation, and the availability of referral networks
to manage complications (9).  Additionally, the lack of
a clear definition regarding the practice scope of skilled
birth  attendants  continues  to  confuse  their  role  in
providing healthcare.  Despite these areas of ambiguity,
Graham  and  colleagues  note  the  positive  impact
attendants may have on reducing maternal mortality, so
long as specific skill sets are mastered and adequate
access to equipment and referral services is available
(27).    
In  considering  only  the  clinical  management  of
postpartum haemorrhage, this review necessarily takes
a  narrow  view  of  the  causes  of  maternal  mortality.
Ronsmans and colleagues describe the other levels at
which  delays  in  access  to  care  can  prove  fatal  to
mothers  experiencing  complications  with  pregnancy
and  delivery.    The  authors  describe  three  potential
delays  to  treatment,  the  first  being  a  delay  in  the
patient’s or family’s recognition of the need to seek care
(3).    This  can  be  further  explained  as  discordance
between  actual  and  perceived  risk,  the  latter  being
partly constituted by attitudes and cultural beliefs such
as, for example, the benefit or normalcy of bleeding
during delivery (29).  Added to this “first delay” would
be a family’s inability to afford care in settings that lack
publically  funded  healthcare.    Uncoordinated  referral
systems and barriers at the community level—including
physical,  financial,  or  cultural—comprise  the  second
delay, while delay in receiving effective interventions is
cited as the third (3).  As mentioned previously, this
review focuses on clinical management strategies, akin
to the interventions necessary to avoid the “third delay”.
Nonetheless,  the  extent  to  which  appropriate
management may improve clinical outcomes is limited
by  factors  described  by  delays  “one”  and  “two”.
Socioeconomic  inequalities  predispose  women  from
poorer backgrounds to increased risk of death during
childbirth, as does the lower social status women hold
in many communities of the developing world (3, 29).
Additionally,  healthcare  systems  in  developing
countries may not be able to provide comprehensive
care to patients as a result of limited access to resources.
In  an  ecological  analysis  of  Latin  American  and
Caribbean countries, Cruz found an inverse association
between  donor  blood  availability  and  both  maternal
mortality  ratios  and  risk  of  death  due  to  postpartum
haemorrhage  (30).      Social  and  cultural  inequalities,
along  with  issues  concerning  the  accessibility  and
comprehensiveness of healthcare, are the antecedents of
maternal  mortality  in  developing  nations.    These
upstream  factors  need  to  be  considered  alongside
clinical management and intervention in the pursuit of
worldwide reduction in maternal deaths.     
SUMMARy OF RECOMMENDATIONS 
This  review  identified  several  evidence-based
recommendations for the prevention and management
of  postpartum  haemorrhage  in  developing  countries.
Broadly, these recommendations relate to AMSTL,the
use  of  uterotonic  therapy,  the  use  of  compression
techniques, and the accurate measurement of blood loss.
These recommendations and their level of evidence are
summarised below.
Recommendations Based on Level A Evidence
1. AMTSL should be practised by clinicians to reduce risk 
of postpartum haemorrhage (10-12).
2. Oxytocin should be used as a uterotonic agent in settings 
where the appropriate storage and administration of this 
medication is possible (13,14).Post-partum Hemorrhages 65 Vol. 12  No. 2
3. In the absence of available oxytocin, misoprostol is an 
effective uterotonic agent and should be used to help 
prevent postpartum haemorrhage (17-19).
Recommendations Based on Level B Evidence
1. Intrauterine tamponade with condom and catheter may be 
used to control severe postpartum haemorrhage refractory 
to medical management (25).
Recommendations Based on Level C Evidence
1. Accurate estimation of blood loss should be standardised 
using a blood collection drape  (21-23).
2. Abdominal compression of the aorta may decrease blood 
loss in severe postpartum haemorrhage (24).
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